Detailed explanation of side effects of EPKINLY (icarelatumumab): an important lesson in medication safety

EPKINLYOne of the most common side effects is cytokine release syndrome (CRS). This is a systemic inflammatory response caused by overactivation of the immune system. Symptoms may include fever, chills, low blood pressure, difficulty breathing, etc. In severe cases, CRS may even be life-threatening. Therefore, while using EPKINLY, patients need to closely monitor their symptoms and seek medical attention immediately if they feel unwell.

In addition to CRS, EPKINLY may also cause immune effector cell-associated neurotoxic syndrome (ICANS). This is a side effect that affects the nervous system and can cause symptoms such as headaches, confusion, and seizures. For patients who develop ICANS symptoms, doctors need to quickly evaluate and take appropriate treatment measures to prevent the condition from worsening.

EPKINLYIt may also affect the blood system, leading to leukopenia, thrombocytopenia, etc. These side effects may increase a patient's risk of infection or bleeding. Therefore, during the period of using EPKINLY, patients need to have regular blood tests to monitor changes in the blood system.

In terms of the digestive system, EPKINLY may also cause nausea, vomiting, diarrhea and other uncomfortable symptoms. These symptoms, although usually mild, can affect a patient's quality of life. Doctors can provide corresponding supportive treatment, such as antiemetics, antidiarrheals, etc., based on the patient's specific conditions.

It is worth noting that EPKINLY may also interact with other drugs, affecting its efficacy or increasing the risk of adverse reactions. Therefore, while using EPKINLY, patients need to inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements. Doctors will evaluate potential interaction risks based on the patient's specific situation and give corresponding medication recommendations.

In order to ensure the patient's medication safety, doctors will conduct a detailed assessment before usingEPKINLY, including the patient's age, physical condition, type and severity of lymphoma, etc. At the same time, the doctor will also explain the side effects and precautions of the drug in detail to the patient to ensure that the patient fully understands and agrees to receive treatment.

Reference materials:https://www.drugs.com/monograph/epcoritamab-bysp.html#dosage